RGMa, is upregulated after central nervous system injury and inhibits neurite outgrowth, contributing to permanent disability. Unasnemab's blockade of RGMa signaling aims to overcome this inhibition, facilitating axonal sprouting, remyelination, and neural plasticity. This approach represents a novel strategy to improve neurological outcomes in conditions where regenerative processes are suppressed.